Global Cutaneous Lupus Erythematosus Market, By Type (Acute, Subacute, Intermittent, Chronic), Drug Class (Retinoids, Corticosteroids, Immunosuppressants, Antimalarial Drugs, Others), Route of Administration (Oral, Injections, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.
Global Cutaneous Lupus Erythematosus Market Analysis and Size
In recent years, the cutaneous lupus erythematosus market is anticipated to grow rapidly during the forecast period. The Lupus Foundation of America estimates that 1.5 million Americans have lupus, with 16,000 new cases recorded each year in the Americas. Lupus is a chronic autoimmune illness in which the body's immune system fails to identify its own cells and tissues and attacks them. Your immune system attacks your skin in cutaneous (skin) lupus. Skin lupus affects about 10% of all lupus cases, while skin lupus affects 65 percent of patients with systemic lupus.
- Data Bridge Market Research analyses that the cutaneous lupus erythematosus market was valued at USD 2,028.24 million in 2021 and is expected to reach USD 5,468.7 million by 2029, registering a CAGR of 13.20% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Global Cutaneous Lupus Erythematosus Market Definition
Cutaneous lupus erythematosus is an autoimmune, chronic variant of lupus erythematosus that mostly affects the skin. The symptoms are Erythema skin, popular or scaly rashes on the arms, ringed shaped lesions, and plaques. Although the specific aetiology of cutaneous lupus erythematosus is unknown, hormones, genetic factors, and environmental triggers may all have a role in the disease's development.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Acute, Subacute, Intermittent, Chronic), Drug Class (Retinoids, Corticosteroids, Immunosuppressants, Antimalarial Drugs, Others), Route of Administration (Oral, Injections, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
LEO Pharma A/S (Denmark), Zydus Cadila (India), Amneal Pharmaceuticals LLC. (US), Glenmark Pharmaceuticals Limited (India), Hikma Pharmaceuticals PLC (UK), Dr. Reddy's Laboratories Ltd. (India), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Bausch Health Companies Inc. (Canada), Eli Lilly and Company (US), AbbVie Inc. (US), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Allergan (Ireland), Merck & Co., Inc. (US), Sumitomo Corporation (Japan), Pfizer Inc. (US), GlaxoSmithKline plc (UK)
|
|
Market Opportunities
|
|
Cutaneous Lupus Erythematosus Market Dynamics
Drivers
- Increasing prevalence of cutaneous lupus erythematosus
The rising prevalence of cutaneous lupus erythematosus is a major driver driving the cutaneous lupus erythematosus market's growth.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of cutaneous lupus erythematosus market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the cutaneous lupus erythematosus market. Additionally, high disposable income and increase in the demand for effective therapies will expand the cutaneous lupus erythematosus market. Along with this, rising geriatric population and continuously changing lifestyle will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the cutaneous lupus erythematosus market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the cutaneous lupus erythematosus market growth during the forecast period.
Restraints/Challenges Global Cutaneous Lupus Erythematosus Market
On the other hand, the high cost associated with the treatment of cutaneous lupus erythematosus will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the cutaneous lupus erythematosus market. Additionally, a decline in clinical visits due to COVID-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of the market during the forecast period of 2022-2029.
This cutaneous lupus erythematosus market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cutaneous lupus erythematosus market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Lupus is far more common in women. Women between the ages of 15 and 44 make up over 90% of those diagnosed with lupus. It is, however, available to persons of all genders and ages. Lupus commonly appears in children at the age of 12.
Cutaneous lupus erythematosus market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Cutaneous Lupus Erythematosus Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems worldwide have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for various reasons, including difficulty accessing a doctor, fear of infection transmission, and inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of cutaneous lupus erythematosus in recent months.
Global Cutaneous Lupus Erythematosus Market Scope
The cutaneous lupus erythematosus market is segmented on the basis of type, drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Acute
- Subacute
- Intermittent
- Chronic
Type segment for the cutaneous lupus erythematosus market is segmented into acute, subacute, intermittent and chronic.
Drug Class
- Retinoids
- Corticosteroids
- Immunosuppressants
- Antimalarial Drugs
- Others
Based on drug class, the cutaneous lupus erythematosus market is segmented into retinoids, corticosteroids, immunosuppressants, antimalarial drugs and others.
Route of Administration
- Oral
- Injections
- Topical
- Others
The route of administration segment for global cutaneous lupus erythematosus market is segmented into oral, injections, inhalation and others.
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
On the basis of end-users, the cutaneous lupus erythematosus market is segmented into hospitals, specialty clinics, homecare and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the cutaneous lupus erythematosus market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.
Cutaneous Lupus Erythematosus Market Regional Analysis/Insights
The Cutaneous lupus erythematosus market is analysed and market size insights and trends are provided by country, type, drug class, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Cutaneous lupus erythematosus market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the cutaneous lupus erythematosus market because of the growing prevalence of cutaneous lupus erythematosus in this region. Additionally, growing focus of major key players on novel technology will further propel the market's growth rate in this region.
Asia-Pacific are expected to grow during the forecast period due to number of population and rising healthcare expenditure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Cutaneous Lupus Erythematosus Market Share Analysis
The Cutaneous lupus erythematosus market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cutaneous lupus erythematosus market.
Some of the major players operating in the cutaneous lupus erythematosus market are:
- LEO Pharma A/S (Denmark)
- Zydus Cadila (India)
- Amneal Pharmaceuticals LLC. (US)
- Glenmark Pharmaceuticals Limited (India)
- Hikma Pharmaceuticals PLC (UK)
- Dr. Reddy's Laboratories Ltd. (India)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Bausch Health Companies Inc. (Canada)
- Eli Lilly and Company (US)
- AbbVie Inc. (US)
- Abbott (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Allergan (Ireland)
- Merck & Co., Inc. (US)
- Sumitomo Corporation (Japan)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
SKU-